I think there is an impetus not to finish it for COVID. We have had three trials demonstrate that Brilacidin is not absorbed into the bloodstream anywhere in the digestive tract to any appreciable extent. That is a great strength for our anti inflammatory indications and a great weakness for anti-viral.
News 
Market Data 
Discover 
